Abstract 1500P
Background
Approximately 50% of deaths worldwide occur in an acute hospital setting. Doctors-in-training (DITs) experience death & dying in many forms and settings, and at every stage of their medical training. They often feel unprepared or unsupported when providing this care, which can cause significant distress. Yet, our experience is that DITs do not receive much, if any, specific training or support in approaching these events. The purpose of this study is to establish the training and education received by DITs in Cork University Hospital in dealing with death and explore the concept of spirituality in relation to their own experiences.
Methods
We performed a qualitative survey of DITs using a 27-question electronic survey. Participants answered questions regarding the prior training or education they had received relating to death and dying, their confidence in recognising and managing dying, and their opinion on the adequacy of the training or support available currently. A modified version of the Spiritual Wellbeing Scale (SWBS) questionnaire, a validated tool to provide an overall measure of perceived spiritual quality of life, was used to assess impact on spirituality.
Results
130 DITs responded to our survey (female=75). 67% disagreed or strongly disagreed (n=87) that they have received adequate training in relation to death & dying. Almost half did not feel confident discussing end-of-life care with patients or their families (n=63), and 69% (n=88) felt that support offered after the death of a patient was inadequate. The vast majority agreed or strongly agreed (n=124) that end-of-life care was important to the delivery of acute care. 71% (n=92) reported that the death of a patient had had a personal impact on them. The median Existential Wellbeing Score was 44 (range 24-59), indicating a moderate sense of life satisfaction. Of note, however, 49% (n=64) responded that they felt unsettled about their future.
Conclusions
Patient deaths frequently impact DITs. This survey highlights the importance of improving the training and supports available to DITs in dealing with death & dying. This has the potential to benefit both DITs, through better wellbeing, and their patients, by improving confidence and competence providing end-of-life care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cork University Hospital Medical Oncology Department.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10